Title: Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNF alpha, improves health-related quality of life in patients with moderate to severe Crohn's disease
Authors: Rutgeerts, Paul ×
Schreiber, Stefan
Feagan, Brian
Keininger, Dorothy L
O'Neil, Liz
Fedorak, Richard N #
Issue Date: Mar-2008
Publisher: Springer International
Series Title: International Journal of Colorectal Disease vol:23 issue:3 pages:289-296
Abstract: Background and aims Certolizumab pegol, a polyethylene glycolated Fc-free Fab' was efficacious and well tolerated in patients with moderate-to-severe Crohn's disease in a previously reported randomized, placebo-controlled study. In this paper, we report the effect of certolizumab pegol on health-related quality of life (HRQoL).
ISSN: 0179-1958
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Translational Research in GastroIntestinal Disorders
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science